Want to join the conversation?
$AGN's Namenda XR revenues for 2Q16 fell 18.7% YoverY to $166.5MM, as a result of lower net selling price and volume. Lumigan/Ganfort revenues slid 0.8% to $175.1MM due to modest prescription declines. Bystolic revenues declined 4.1% to $150.7MM, due to modest decline in overall prescriptions.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.